JYPC(SZ:002198) Jing Ji Guan Cha Wang·2025-08-04 07:05Core Viewpoint - On August 1, 2023, Jiaying Pharmaceutical (002198) received an administrative penalty notice from the Guangdong Regulatory Bureau of the China Securities Regulatory Commission (CSRC) for failing to timely disclose 220 million yuan in related party fund borrowing, resulting in fines for the company and its responsible persons [1][2]. Group 1: Administrative Penalties - Jiaying Pharmaceutical was fined 1.5 million yuan, while its chairman Li Neng was fined 160,000 yuan, general manager You Yongping 100,000 yuan, and former financial director Shi Junping 80,000 yuan, totaling 4.9 million yuan [1][2]. - The violations involved non-operating fund transactions that were not disclosed until the 2024 annual report, constituting a breach of the Securities Law [2]. Group 2: Company Background - Jiaying Pharmaceutical is a traditional Chinese medicine manufacturer established in 2003, with R&D, production, and sales bases in Changsha, Hunan Province, and Meizhou, Guangdong Province [3][4]. - As of August 4, 2025, the company's total market value was 3.517 billion yuan, with a product portfolio that includes 70 approved drug varieties across various therapeutic areas [4].